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Archival formalin-fixed paraffin-embedded (FFPE) tissues represent an extraordinary
source of smallRNAs, including microRNAs (miRNAs). Contrary to other RNA molecules,
miRNAs are stable, nuclease-resistant and quantifiable even in low quality samples.
The accurate assessment of miRNA levels in archival samples is of great interest for
many pathological conditions, including cancer. In human tumors, microRNA expression
is type-specific and can be used as diagnostic, prognostic or response-to-treatment
biomarker. In this study, we provide a method for multiple miRNA quantification in 96-well
plates, using EvaGreen-based droplet digital PCR technology andmiRCURY LNAmiRNA
assays. This approach allows the absolute quantification of a customizable panel of
miRNAs at the same time and under identical experimental conditions, to be used for
diagnostic or prognostic applications.
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INTRODUCTION
MicroRNAs (miRNAs) are important molecules involved in post-transcriptional regulation of gene
expression. Their crucial role in human cancer is well documented (1). MicroRNA expression
profiles can distinguish different cancer types and contribute to cancer sub-classification (2).
The pattern of miRNA expression can be used to infer the origin site of metastatic tumors
(3–5). In addition, the value of microRNAs as molecular biomarkers in formalin-fixed paraffin-
embedded (FFPE) specimens and body fluids, and the many applications of miRNA quantification
for diagnosis and prognosis in several human cancers were also described (6). MicroRNAs are
highly stable molecules that resist to RNAase activity in FFPE specimens, which are the most
widely available clinical archival samples, biological fluids, and also microvescicles and can be easily
isolated from all these tissues (7–9).
Droplet Digital PCR (ddPCR) is a relatively newborn technology that has been used for several
applications, such as rare DNA mutation detection, copy number variation analysis and absolute
nucleic acid quantification (10–12). This assessment can be performed using both dsDNA-binding
dye EvaGreen-based chemistry or TaqMan probe-based assays.
Droplet digital PCR technology (Bio-Rad patent) consists in sample partitioning into nanoliter-
sized water-in-oil droplets, which generates thousands of multiple individual reactions measured
as endpoint PCRs. Droplets are then individually analyzed by a fluorescence detector and classified
as positive if fluorescence is detected (i.e., the target sequence is included) or negative if not.
Finally, the number of positive droplets is used to estimate the target concentration with the
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application of Poisson correction. Specifically, the real
concentration could be underestimated because this technology
cannot distinguish droplets with multiple copies of the target
molecule. Poisson correction solves this problem, by estimating
the number of multiple-target droplets on droplet total number
(10, 13).
This powerful technology has many applications in research
and diagnostics (12, 14). Droplet digital PCR overcomes the
limits of quantitative PCR (qPCR) in performance and accuracy,
eluding several problems connected to qPCR methodology,
such as the need of reference genes for normalization or
replicate samples (15). In a previous study, we assessed the
overall precision and accuracy, as well as intra- and inter-assay
reproducibility, of EvaGreen-based ddPCR with above standard
results (16). Using ddPCR it is also possible to evaluate the
expression of specific miRNAs that circulate in biological fluids,
including blood (17).
METHODS
Objectives and Validation of the Method
In this article we describe a tool for miRNA multi-assay
quantification using RNA obtained from FFPE tissues and
EvaGreen-based droplet digital PCR technology. Multiple
miRNA quantification with ddPCR technology in the same
plate has never been performed and could be quite challenging
because the optimal annealing temperature and primer amount
could change between different miRNA primer sets (16, 18). For
multiplemiRNAquantification, we had to use the same annealing
temperature and primer amount. To achieve this goal, we selected
the experimental conditions that were most efficient for the
majority of the single assays we tested in the past (18, 19), which
were 58◦C annealing temperature and 1 µL primer amount.
Then, we designed pre-spotted custom plates (96-well format)
with 92 different miRCURY LNA miRNA primers (Qiagen,
former Exiqon). Using this approach, we were able to assess the
expression of 92 different miRNAs at the same time, using the
same amount of primer and the same PCR conditions (16, 18).
Detailed Protocol
Here we present a detailed protocol of our approach for multiple
miRNA quantification with ddPCR, with the sequential steps
necessary to use this method.
RNA Extraction From FFPE Samples
We collected 4–5 tissue slices 10–20µm thick from 14 diagnostic
archival formalin-fixed paraffin embedded (FFPE) blocks
from 14 different tumor types. The study was approved by
the local ethical committee (Comitato Etico Indipendente
dell’Azienda Ospedaliero-Universitaria di Bologna, Policlinico
S.Orsola Malpighi). All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Pathological characteristics of cancer patients are detailed in
Supplementary Table 1.
With the assistance of a Haematoxylin and Eosin (H&E)
stained section, we dissected the best tumor area and placed in
2mL Eppendorf tubes (cat. no. H0030120094).
Total RNA can be isolated using any standard method
and commercial kit currently available. We describe herein a
protocol for the isolation of RNA from FFPE samples using
the RecoverAll Total Nucleic Acid Isolation Kit for FFPE
(Ambion/ThermoFisher, cat. no. AM1975). In detail, FFPE
tumor sections underwent paraffin removal, by adding 1mL
of 100% xylene and incubating at 50◦C for 3min. After
centrifugation, xylene was removed without disturbing the pellet;
this was then washed twice with 1mL of 100% ethanol and left
to air dry 45min at room temperature, to remove any residual
ethanol. Protease digestion was performed adding 200 µL of
Digestion Buffer and 4 µL of Protease enzyme. Samples were left
to incubate for 15min at 50◦C and 15min at 80◦C in heat blocks.
The Isolation mix was then prepared, mixing 240 µL of Isolation
Additive with 550 µL of 100% ethanol, and added to the sample.
All this mixture was then passed through a filter cartridge and
collected in a collection tube through centrifugation at 10000 g
for 30 s. The filter was then washed firstly with 700 µL of Wash
1 solution and then with Wash 2/3 solution and centrifuge to
remove any residual fluid. A mixture containing 6 µL of 10X
DNase buffer, 4 µL of DNase and 50 µL of Nuclease free water
was added to the center of the filter and left to incubate 30min at
room temperature. After repeating the washes with Wash 1 and
Wash 2/3 solutions, filter underwent to the elution of RNA with
60 µL of nuclease-free water.
RNA quality and quantity were assessed by Nanodrop
spectrophotometer (ThermoFisher) and frozen at−80◦C.
cDNA Synthesis
The conversion of RNA to cDNA was performed using the
Universal cDNA synthesis kit II (Exiqon, cat. no. EX203301PR),
following the manufacturer’s protocol.
RNA was diluted to a concentration of 5 ng/µL using
nuclease-free water. The mixture for reverse transcription was
prepared for each sample mixing: 2 µL of 5x Reaction Buffer,
4.5 µL of nuclease free water, 1 µL of enzyme mix, 0.5 µL of
synthetic RNA (Sp6) spike-in and 2 µL of diluted RNA (10 ng
of total RNA). The reaction was performed in a conventional
thermal cycler and comprised an incubation step (60min at
42◦C), enzyme heat inactivation (5min at 95◦C) and a holding
step (4◦C forever). Resulting cDNA was then conserved at
−20◦C in 1.5mL LoBind DNA Eppendorf tubes (cat. no. H 0030
108 051).
cDNA Dilution
Just before the next steps, cDNA was diluted 1:50. A further
dilution of 1:10 (final 1:500) was prepared to assess one very
abundant microRNA (miR-21-5p) and the internal control
assay UniSP6, in order to avoid the saturation of the positive
droplets.
miRNA Plate Setup
Pre-spotted custom plates including 89 different cancer-specific
miRNA primer sets were designed usingmiRCURY LNACustom
PCR Panel (Qiagen, former Exiqon) in the 96-well format (cat.
no. 339330, cat. no. 339332). Three additional assays for small
non-coding RNAs (SNORD44, SNORD48 e snRNAU6) were
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included as reference. The remaining wells contained two inter-
plate calibrator assays (UniSp3), a control plate assay (UniSP6)
and a no template control (NTC) well.
Pre-spotted custom plates have both forward and reverse PCR
amplification primers in an amount that would be sufficient for
one qPCR reaction. We tested these primers as individual assays
(16), and verified that this amount is excessive for EvaGreen-
based ddPCR, because of the broad fluorescence amplitude of the
negative signal. Half the amount was the best solution for ddPCR
testing. Thus, we split the plate primers in two plates, as described
in the next step.
Droplet Generation and PCR
Droplet digital PCR workflow was performed using a miRNA
quantification protocol that was recently developed (6, 18) using
a 20 µL volume of PCR mix containing 10 µL of 2X QX200
ddPCR EvaGreen Supermix (Bio-Rad, cat. no. 1864034), 6 µL of
nuclease-free water and 4 µL of diluted cDNA.
To split into two plates the pre-spotted primers, we re-
suspended each well in a double amount of EvaGreen and water
and transferred half amount in a second plate (Eppendorf, cat.
no. H 0030 128 605). At the end of this step, we obtained two 96-
well plates with half amount of primers in a volume of 16µL, both
ready for the addition of the diluted cDNA, which was performed
with a multichannel pipet.
Each ddPCR assay mixture was loaded into a disposable DG8
Cartridge (Bio-Rad, cat. no. 1864008) located into a cartridge
holder (Bio-Rad, cat. no. 1863051). Then, 70 µL of droplet
generation oil for EvaGreen (Bio-Rad, cat. no. 1864005) was
loaded into each of the eight oil wells. The cartridge was then
covered with a DG8 Gasket (Bio-Rad, cat. no. 1863009) and
placed inside the QX200 Droplet Generator (Bio-Rad, cat. no.
1864002). Upon completion of droplet generation, the droplets
were carefully transferred to a new Eppendorf blue twin.tec
96-well PCR plate (cat. no. H 0030 128 605). The plate was
heat-sealed with a pierceable aluminum foil (Bio-Rad, cat. no.
1814040) into the PX1 PCR Plate Sealer (Bio-Rad, cat. no.
1814000) and placed in a thermal cycler. Thermal cycling
conditions were: 95◦C for 5min, then 40 cycles of 95◦C for 30 s
and 58◦C for 1min and three final steps at 4◦C for 5min, 90◦C for
5min and a 4◦C infinite hold. It is mandatory to use a ramping
rate of 2◦C/second in every step.
Droplet Reading and Data Analysis
After PCR is completed, the sealed plate was transferred into
the plate holder of the QX200 Droplet Reader (Bio-Rad, cat. no.
1864003). Using QuantaSoft software (Bio-Rad), the analysis was
set up and started in order to analyze the droplets with an optical
detector. At the end of the plate reading, the resulting data were
analyzed with QuantaSoft software v1.7. Specifically, from the 2D
amplitude plot, the positive droplets in each well were selected
using the lasso tool. This function allows to manually select the
positive cloud by drawing a circle around it, and finally obtain the
miRNA amount (copies/µL). Using the events tab, the number of
positive and total generated droplets were evaluated. The general
performance of EvaGreen ddPCR consented to obtain a total
number of 18,000–21,000 droplets per well.
RESULTS
Reproducibility
To demonstrate the reproducibility of this multiple
quantification approach, the same sample was assessed twice
using the procedure above described. Pearson correlation
analysis was performed to assess the correlation between
replicates. Comparing the miRNA expression in the two
samples the p-value resulted highly significant (P < 0.0001).
Pearson r was found to be 0.9537 (0.92–0.97 95% confidence
interval), indicating a strong reproducibility of the methodology
(Figure 1).
Application and Effectiveness
Using this multiple miRNA quantification tool, we evaluated
the miRNAs expression of 14 FFPE samples from different
tumor types (liver, skin, breast, gastric, endometrium, testis, GI-
neuroendocrine, prostate, urothelial, kidney, colon, pancreas,
lung, ovary).
Our custom plate was designed to contain the most cancer-
specific miRNAs: specifically, 89 cancer-specific miRNAs and 3
reference genes.
As shown in Figure 2, we were able to obtain a good
separation between positive and negative droplets for all the
miRNA assays in our panel. The above detailed experimental
conditions allowed a reliable and efficient quantification of all the
targets in the same experiment. In Figure 3 we represented some
2D plots of different miRNA assays: the shape of the positive
clouds could vary between targets, but it is still easily selectable
with the above mentioned QuantaSoft lasso tool.
We obtained an average total number of droplets of 20,000
(Figure 4), thus confirming the high sensitivity of the method
and accurate detection even of rare targets.
One of the many applications of this tool is represented
by the analysis of miRNA expression profile in cancer. By
FIGURE 1 | Correlation between replicates. The same 92-miRNA panel was
assessed twice in the same sample. Results were highly concordant (Pearson
r = 0.9537). Each dot represents a microRNA. The miRNA absolute
expression is presented as copies per microliter of the amplification reaction
mixture. Axis scale is log2 transformed.
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FIGURE 2 | 1D Plot representation. Droplet distribution for different miRNA assays evaluated in the same sample. 1D Plot representation shows positive (blue) and
negative (black) droplet amplitudes. The fluorescence amplitude can change according to the assay.
FIGURE 3 | Positive droplet selection in 2D Plot. Bi-dimensional droplet plots of four illustrative miRNA assays: (A) RNU6, (B) miR-149-5p, (C) miR-24-3p, and (D)
miR-210-3p. Droplet clouds could have different appearance and shapes, but droplet positive selection is always possible.
analyzing different cancer types, we were able to validate
the expected miRNA signatures, in agreement with our
previous data obtained with microarray technology (4).
The miRNA profile of 14 different tumor samples is shown
in Figure 5. Although we could not directly compare the
miRNA quantification provided by a probe hybridization-based
technology (Agilent microRNA microarray) and a digital
PCR technology, we analyzed the correlation in microRNA
quantification between these two approaches, after data
normalization, and observed a highly significant correlation of
the data (p < 0.0001, Spearman r > 0.7) for all the tested cancer
types.
DISCUSSION
Advantages and Limitations
Our miRNA multi-assay tool suits the need for a simultaneous
absolute quantification of different miRNA targets. The detection
of up to 92 different targets all at once and in the same ddPCR
experiment, consents to adjust the use of this method for any user
need.
We demonstrated that using EvaGreen based-ddPCR and
our PCR conditions the quantification of all targets was
efficient and reproducible, despite starting from low quality
material as FFPE tissue. This novel approach can be particularly
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FIGURE 4 | Number of events. Total number of positive (blue) and negative (green) droplets visualized in QuantaSoft software (Bio-Rad) for each miRNA assay
assessed in the same tumor sample.
FIGURE 5 | miRNA profile in human cancers. The 89-miRNA expression profile (normalized on reference genes) across 14 different cancer types, as detected by our
ddPCR multi-assay method. Each tumor displays a specific miRNA expression profile.
appropriate when the miRNAs are expressed at low levels
and wouldn’t be detected by standard quantitative PCR. Other
studies have already proved ddPCR superior accuracy, which
overcomes the need of replicates and reduce the experimental
costs (15, 16).
Since this tool provides the quantification of up to 92 miRNAs
per experiment, it is necessary to identify a focused custom
panel of interest. It is important to pay attention to the step of
droplet selection during the analysis, and carefully distinguish the
positive from the negative droplets. This is a critical step andmust
be done analyzing each well one-by-one in the 2D amplitude
plot and selecting the positive cloud manually with the available
software tools.
Even if in some cases the separation could be further
optimized (e.g., changing the annealing temperature or the
amount of primer), for all the assays that were tested in our
experiment a good separation between positive and negative
droplets was obtained.
The method described in this paper represents a remarkable
innovation. Indeed, the multiple miRNA quantification with
ddPCR in the same experiment has never been described. In
addition, the possibility to extend this approach to archival
samples could support and improve disease biomarker discovery
and validation.
Given the sensibility and flexibility of this method,
possible applications include: discovery or validation of
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miRNA biomarkers; miRNA quantification in every type of
human tissue, including FFPE, biological fluids and fresh
tissue; absolute quantification of multiple miRNAs at the
same time in subcellular compartments (e.g., exosomes and
microvescicles).
AUTHOR CONTRIBUTIONS
NL, MG, and EP carried out the experiments and drafted the
initial manuscript. MF reviewed the results and wrote the paper.
All authors reviewed and approved the final manuscript as
submitted.
FUNDING
This work was supported by grants from the Italian Association
for Cancer Research (AIRC) to MF (IG 18464) and Fondazione
Pallotti (University of Bologna) to MF. EP was a Fondazione
Veronesi research fellow.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2018.00447/full#supplementary-material
REFERENCES
1. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer:
from research to therapy. J Cell Sci. (2007) 120:1833–40. doi: 10.1242/jcs.03450
2. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F,
et al. A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. (2006) 103:2257–61.
doi: 10.1073/pnas.0510565103
3. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, ZepeniukM, et al.
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. (2008)
26:462–9. doi: 10.1038/nbt1392
4. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafà R, Magri E, et al.
MicroRNA profiling for the identification of cancers with unknown primary
tissue-of-origin. J Pathol. (2011) 225:43–53. doi: 10.1002/path.2915
5. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB,
et al. A second-generationmicroRNA-based assay for diagnosing tumor tissue
origin. Oncologist (2012) 17:801–12. doi: 10.1634/theoncologist.2011-0466
6. Ferracin M, Negrini M. Micromarkers 2.0: an update on the role of
microRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. (2015)
15:1369–81. doi: 10.1586/14737159.2015.1081058
7. Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska
AE. Evaluation and validation of total RNA extractionmethods for microRNA
expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn.
(2008) 10:203–11. doi: 10.2353/jmoldx.2008.070153
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-
Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers
for cancer detection. Proc Natl Acad Sci USA. (2008) 105:10513–8.
doi: 10.1073/pnas.0804549105
9. Peiro-Chova L, Pena-Chilet M, Lopez-Guerrero JA, Garcia-Gimenez JL,
Alonso-Yuste E, Burgues O, et al. High stability of microRNAs in
tissue samples of compromised quality. Virchows Arch. (2013) 463:765–74.
doi: 10.1007/s00428-013-1485-2
10. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz
AJ, et al. High-throughput droplet digital PCR system for absolute
quantitation of DNA copy number. Anal Chem. (2011) 83:8604–10.
doi: 10.1021/ac202028g
11. Perkins G, Lu H, Garlan F, Taly V. Droplet-based digital PCR:
application in cancer research. Adv Clin Chem. (2017) 79:43–91.
doi: 10.1016/bs.acc.2016.10.001
12. Karlin-Neumann G, Bizouarn F. Entering the pantheon of 21(st) century
molecular biology tools: a perspective on digital PCR. Methods Mol Biol.
(2018) 1768:3–10. doi: 10.1007/978-1-4939-7778-9_1
13. Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat
S, et al. Evaluation of a droplet digital polymerase chain reaction format
for DNA copy number quantification. Anal Chem. (2012) 84:1003–11.
doi: 10.1021/ac202578x
14. Day E, Dear PH, Mccaughan F. Digital PCR strategies in the development and
analysis of molecular biomarkers for personalized medicine. Methods (2013)
59:101–7. doi: 10.1016/j.ymeth.2012.08.001
15. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson
BJ, et al. Absolute quantification by droplet digital PCR versus analog
real-time PCR. Nat Methods (2013) 10:1003–5. doi: 10.1038/nmet
h.2633
16. Miotto E, Saccenti E, Lupini L, Callegari E, Negrini M, Ferracin M.
Quantification of circulating miRNAs by droplet digital PCR: comparison
of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers
Prev. (2014) 23:2638–42. doi: 10.1158/1055-9965.EPI-14-0503
17. Ferracin M, Negrini M. Quantification of circulating microRNAs
by droplet digital PCR. Methods Mol Biol. (2018) 1768:445–57.
doi: 10.1007/978-1-4939-7778-9_25
18. Ferracin M, Salamon I, Lupini L, Miotto E, Sabbioni S, Negrini M. Circulating
microRNA quantification using DNA-binding dye chemistry and droplet
digital PCR. J Vis Exp. (2016). doi: 10.3791/54102
19. Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi MV, Rocchi A, et al.
Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget
(2015) 6:14545–55. doi: 10.18632/oncotarget.3859
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Laprovitera, Grzes, Porcellini and Ferracin. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 6 October 2018 | Volume 8 | Article 447
